Live Quote · NASDAQCDMOHealthcare· Biotechnology

Avid Bioservices, Inc.

$12.49 0.00%(+$0.00)
TickerSpark Score
50/100
Mixed
70
Valuation
20
Profitability
10
Growth
52
Health
100
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CDMO research report →

52-Week Range100% of range
Low
$5.90
Current
$12.49
High
$12.51
Company Overviewwww.avidbio.com

About the company

Avid Bioservices, Inc. operates as a Contract Development and Manufacturing Organization (CDMO), specializing in the development and CGMP-compliant production of biopharmaceutical drug substances. Their core expertise lies in compounds derived from mammalian cell culture, providing both clinical and commercial scale manufacturing solutions.

CEO
Nicholas Stewart Green MBA
IPO
1994
Employees
371
HQ
Tustin, CA, US

Price Chart

+91.56% · this period
$12.49$9.29$6.09Feb 06Aug 07Feb 06
Valuation
Market Cap
$798.90M
P/E
-5.60
P/S
5.71
P/B
12.96
EV/EBITDA
-84.37
Div Yield
0.00%
Profitability
Gross Margin
5.23%
Op Margin
-13.35%
Net Margin
-100.60%
ROE
-112.44%
ROIC
-6.95%
Growth & Income
Revenue
$139.91M · -6.27%
Net Income
$-140,753,000 · -25234.46%
EPS
$-2.23 · -24877.78%
Op Income
$-18,678,000
FCF YoY
76.96%
Performance & Tape
52W High
$12.51
52W Low
$5.90
50D MA
$12.36
200D MA
$10.25
Beta
1.41
Avg Volume
1.58M

Get TickerSpark's AI analysis on CDMO

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Feb 5, 25Ziebell Mark Rsell14,286
Feb 5, 25Ziebell Mark Rsell21,429
Feb 5, 25Ziebell Mark Rsell1,733
Feb 5, 25Ziebell Mark Rsell98,120
Feb 5, 25Ziebell Mark Rsell17,679
Feb 5, 25Ziebell Mark Rsell51,413
Feb 5, 25Ziebell Mark Rsell55,310
Feb 5, 25Ziebell Mark Rsell108,579
Feb 5, 25Ziebell Mark Rsell66,799
Feb 5, 25Thoma Jeannesell45,611
Coverage · CDMO

Our CDMO coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on CDMO yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate CDMO report →
Internal Compare

Similar companies

Peers in the same neighborhood.